Tay-Sachs disease: current perspectives from Australia

DOI: 10.2147/tacg.s49628
The Application of Clinical Genetics, 2015, 8, 19-25.

#	Paper	IF	Citations
31	Harnessing the Flow of Excitation: TRP, Voltage-Gated Na(+), and Voltage-Gated Ca(2+) Channels in Contemporary Medicine. *Advances in Protein Chemistry and Structural Biology*, **2016**, 103, 25-95	5.3	3
30	Neurodegenerative Diseases. **2016**, 161-175		
29	Protecting the future well: access to preconception genetic screening and testing and the right not to use it. *Griffith Law Review*, **2016**, 25, 71-86	0.2	2
28	Thalamic T2 hypointensity: a diagnostic clue for Tay-Sachs disease. *Acta Neurologica Belgica*, **2016**, 116, 195-7	1.5	3
27	Mutation Frequency of Three Neurodegenerative Lysosomal Storage Diseases: From Screening to Treatment?. *Archives of Medical Research*, **2017**, 48, 263-269	6.6	2
26	Tay-Sachs Disease. **2017**, 2725-2732		
25	New Approaches to Tay-Sachs Disease Therapy. *Frontiers in Physiology*, **2018**, 9, 1663	4.6	37
24	Progranulin associates with hexosaminidase A and ameliorates GM2 ganglioside accumulation and lysosomal storage in Tay-Sachs disease. *Journal of Molecular Medicine*, **2018**, 96, 1359-1373	5.5	20
23	Measuring the impact of genetic knowledge on intentions and attitudes of the community towards expanded preconception carrier screening. *Journal of Medical Genetics*, **2018**, 55, 744-752	5.8	23
22	Genetics and Therapies for GM2 Gangliosidosis. *Current Gene Therapy*, **2018**, 18, 68-89	4.3	47
21	Metabolomics for Investigating Physiological and Pathophysiological Processes. *Physiological Reviews*, **2019**, 99, 1819-1875	47.9	196
20	Screening for Tay-Sachs disease carriers by full-exon sequencing with novel variant interpretation outperforms enzyme testing in a pan-ethnic cohort. *Molecular Genetics & Genomic Medicine*, **2019**, 7, e836	2.3	7
19	Genomic Testing for Human Health and Disease Across the Life Cycle: Applications and Ethical, Legal, and Social Challenges. *Frontiers in Public Health*, **2019**, 7, 40	6	17
18	A feasibility study of mHealth and wearable technology in late onset GM2 gangliosidosis (Tay-Sachs and Sandhoff Disease). *Orphanet Journal of Rare Diseases*, **2020**, 15, 199	4.2	2
17	In silico analysis of the effects of disease-associated mutations of Ehexosaminidase A in Tay-Sachs disease. *Journal of Genetics*, **2020**, 99, 1	1.2	2
16	Detection of mutant genes with different types of biosensor methods. *TrAC - Trends in Analytical Chemistry*, **2020**, 126, 115860	14.6	15
15	CRISPR-Cas9 for treating hereditary diseases. *Progress in Molecular Biology and Translational Science*, **2021**, 181, 165-183	4	4

14	GM2-gangliosidosis, type I (Tay Sachs disease) in the pediatrician practice. *Pediatriska Farmakologi*, **2021**, 17, 529-535	0.5	
13	Novel HEXA variants in Korean children with Tay-Sachs disease with regression of neurodevelopment from infancy. *Molecular Genetics & Genomic Medicine*, **2021**, 9, e1677	2.3	0
12	In-silico screening and microsecond molecular dynamics simulations to identify single point mutations that destabilize hexosaminidase A causing Tay-Sachs disease. *Proteins: Structure, Function and Bioinformatics*, **2021**, 89, 1587-1601	4.2	1
11	Serum Cytokine Profile, Beta-Hexosaminidase A Enzymatic Activity and GM Ganglioside Levels in the Plasma of a Tay-Sachs Disease Patient after Cord Blood Cell Transplantation and Curcumin Administration: A Case Report. *Life*, **2021**, 11,	3	1
10	Encyclopedia of Pathology. *Encyclopedia of Pathology*, **2016**, 1-2	0	
9	Tay-Sachs Disease. **2016**, 1-8		
8	Niemann, Albert (1880 1921). *Encyclopedia of Pathology*, **2017**, 405-406	0	
7	Thirty two novel nsSNPs May effect onHEXAprotein Leading to Tay-Sachs disease (TSD) Using a Computational Approach.		
6	Genetic-Ancestry Analysis on >93,000 Individuals Undergoing Expanded Carrier Screening Reveals Limitations of Ethnicity-Based Medical Guidelines.		
5	Juvenile tay sachs disease due to compound heterozygous mutation in hex-a gene, with early sign of bilateral tremors. *Annals of Indian Academy of Neurology*, **2022**,	0.9	0
4	Gene Therapy for Rare Neurological Disorders.. *Clinical Pharmacology and Therapeutics*, **2022**,	6.1	1
3	Therapeutic Strategies For Tay-Sachs Disease. *Frontiers in Pharmacology*, 13,	5.6	0
2	Strategies to combat Tay-Sachs disease. **2022**, 337-349		0
1	Doen de Tay-Sachs: relato de caso. **2023**, 82,		0